Abstract:The beta-catenin pathway plays a critical role in the pathogenesis of certain types of cancers. To gain insight into mechanisms by which altered receptor tyrosine kinases regulate cytoplasmic beta-catenin accumulation, the effect of an oncogenic receptor originated from Nantes (RON) variant on beta-catenin accumulation and the role of beta-catenin in RON-mediated tumorigenic activities were studied. In NIH3T3 cells harboring oncogenic variant RON Delta 160, increased beta-catenin accumulation with tyrosine phosphorylation and nuclear translocation was observed. Overexpression of RON Delta 160 also resulted in increased expression of beta-catenin target genes c-myc and cyclin D1. By analyzing cellular proteins that regulate beta-catenin stabilities, it was found that RON Delta 160 activates the protein disheveled (DVL) and inactivates glycogen synthase kinase-3 beta by Ser-9 residue phosphorylation. These effects were channeled by RON Delta 160-activated PI 3-kinase-AKT pathways that are sensitive to specific inhibitors, such as wortmannin, but not to other chemical inhibitors. Silencing RON Delta 160 expression by specific small interfering RNA blocked not only beta-catenin expression but also c-myc and cyclin D1 expression, suggesting that RON expression is required for the activation of the beta-catenin signaling pathway. Moreover, it was found that knockdown of the beta-catenin gene expression by small interfering RNA techniques reduces significantly the RON Delta 160-mediated NIH3T3 cell proliferation, focus-forming activities and anchorage-independent growth. Thus, the oncogenic RON variant regulates beta-catenin stabilities through activation of DVL and inactivation of glycogen synthase kinase-3 beta. The activated beta-catenin cascade is one of the pathways involved in tumorigenic activities mediated by the oncogenic RON variant.

Rnd proteins: multifunctional regulators of the cytoskeleton and cell cycle progression

The RND1 Small GTPase: Main Functions and Emerging Role in Oncogenesis

Rnd Proteins Function as RhoA Antagonists by Activating p190 RhoGAP

Rho Subfamily Proteins in Cancer Invasion and Metastasis

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

Small GTPase RhoE/Rnd3 is a critical regulator of Notch1 signaling.

RND1 is Up-Regulated in Esophageal Squamous Cell Carcinoma and Promotes the Growth and Migration of Cancer Cells.

The Rho GTPase RhoB regulates cadherin expression and epithelial cell-cell interaction

Rnd3 is necessary for the correct oligodendrocyte differentiation and myelination in the central nervous system

Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility

Rho GTPases: Regulation and roles in cancer cell biology

Alterations in a Defined Extracellular Region of the RON Receptor Tyrosine Kinase Promote RON-mediated Motile and Invasive Phenotypes in Epithelial Cells.

An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels

Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.

RhoB regulates cell migration through altered focal adhesion dynamics

Rnd3 Expression is Necessary to Maintain Mitochondrial Homeostasis but Dispensable for Autophagy

Rho GTPases in cancer: friend or foe?

RhoB Acts As a Tumor Suppressor That Inhibits Malignancy of Clear Cell Renal Cell Carcinoma

Targeting Rho GTPase Signaling Networks in Cancer

RhoA-ROCK2 signaling possesses complex pathophysiological functions in cancer progression and shows promising therapeutic potential

Rho: theme and variations